查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2001055

新冠病毒即时检测试剂盒市场：2026-2032年全球市场预测（按产品类型、检测技术、检体类型、分销管道、应用和最终用户划分）

COVID-19 Detection PoC Kits Market by Product Type, Detection Technology, Sample Type, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，COVID-19 检测概念验证试剂盒市场价值将达到 38.6 亿美元，到 2026 年将成长至 41.4 亿美元，到 2032 年将达到 62.8 亿美元，复合年增长率为 7.18%。

主要市场统计数据
基准年 2025 38.6亿美元
预计年份：2026年 41.4亿美元
预测年份 2032 62.8亿美元
复合年增长率 (%) 7.18%

这篇权威的介绍概述了疫情期间的快速创新如何在临床环境和分散环境中发展成为一个复杂且永续的诊断生态系统。

新冠病毒检测的概念验证（PoC）试剂盒格局已从最初的紧急应变演变为诊断韧性中一个复杂且持久的组成部分。在疫情初期，快速检测和紧急使用授权的开发优先考虑的是速度而非规模，但在随后的几年里，稳健性、供应连续性和与临床工作流程的整合变得至关重要。这种演化在产业内催生了一个多层次的生态系统，其中包括为各种环境（从集中式检查室到分散式即时检测点）设计的耗材、仪器和试剂盒。

对重新定义概念验证(PoC) 测试、重塑诊断工作流程、供应链弹性和技术融合的关键结构性变化进行策略分析。

概念验证 (PoC) 检测试剂盒的格局正受到多项变革性变化的影响，这些变化共同重塑了相关人员制定检测策略和产品开发的方式。首先，诊断工作流程的去中心化是一项核心挑战。医疗系统和私人医疗机构越来越倾向于选择能够在传统检查室之外提供可靠结果的 PoC 解决方案，这促使製造商优先考虑以用户为中心的设计、简化的检体采集流程以及与数位化报告平台的整合。随着时间的推移，监管机构也调整了针对这些去中心化工具的核准流程。这加速了 PoC 的普及，同时也提高了人们对上市后监管和实际应用性能证据的期望。

对关税主导的贸易趋势如何重塑整个诊断供应链的采购、製造本地化和成本结构进行严格评估。

关税措施的实施对新冠病毒检测即时检验试剂盒的整个价值链产生了连锁反应，影响到原料、成品以及跨境分销策略。关税改变了耗材和设备的到货成本，促使製造商和采购团队重新评估其筹资策略和库存计划。对于依赖海外生产的专用零件的製造商而言，关税可能会促使其将生产转移到近岸地区或与替代供应商建立合作关係。虽然这可能有助于提高长期抗风险能力，但短期内也可能需要投入资金进行流程认证。

以细分市场主导的综合观点，确定产品设计、监管证据和分销策略的交集，最大限度地提高产品采用率和临床效用。

细分市场分析为理解即时检测试剂盒市场中创新、应用和商业性机会的交汇点提供了一个框架。从产品类型（耗材、仪器、试剂盒）的观点来看，不同的营运和商业考量都会显现出来。耗材需要大量、持续的供应和严格的品管；仪器需要论证资本投资的合理性并提供生命週期支援；而试剂盒则将试剂和说明书以针对特定使用环境优化的形式组合在一起。每个类别都有不同的采购週期和支援需求，这些都会影响供应商的市场进入策略。

详细的区域分析解释了法律规范、製造能力和医疗保健服务模式如何影响即时诊断解决方案的采用差异。

区域趋势对概念验证（PoC）诊断产品的开发、监管和部署有显着影响。在美洲，法规结构的多样性与完善的私人医疗保健网络和强大的购买力并存。这加速了先进即时检测设备的部署，同时也催生了对价格适中的自测和监测工具的在局部需求。该地区庞大的国内製造业基础可用于缓解供应链中断，但都市区之间的医疗资源取得差异依然存在，因此需要采取差异化的分销策略。

透过证据检验策略伙伴关係、平台模组化和整体解决方案的交付如何重新定义诊断开发领域的竞争优势。

在即时检测（PoC）领域，企业间的竞争行为以快速的产品改进、策略伙伴关係和灵活的经营模式为特征。製造商正日益推行模组化平台策略，以便快速重新配置检测方法和试剂，从而应对不断变化的病原体生物学特性和市场需求。与试剂供应商、契约製造和软体整合商建立策略伙伴关係，对于缩短产品上市时间和扩大分销管道至关重要。

为领导者提供切实可行的策略建议，以建立具有韧性的供应链，增强以用户为中心的设计，并调整经营模式以适应不断变化的医疗保健需求。

产业领导者应采取多管齐下的策略，优先考虑供应链韧性、以使用者为中心的设计和策略性商业化，以充分掌握不断增长的即时诊断（PoC）需求。首先，应透过选择替代供应商、对关键试剂和组件采用双重采购模式以及投资区域製造能力，实现供应链多元化并降低对单一供应商的依赖。这将有助于快速响应区域需求激增，同时降低贸易中断和关税波动带来的风险。

我们高度透明的调查方法，结合对关键相关人员的访谈和严格的二次检验，在不依赖数值市场预测的情况下，产生可操作且符合道德规范的见解。

支持这些研究结果的调查方法结合了结构化的一手研究和系统的二手研究，以确保结果的可靠性和检验。一手研究的关键输入包括对价值链上各相关人员（产品开发人员、采购负责人、临床用户、分销合作伙伴和监管顾问）进行的半结构化访谈，以了解营运实际情况、产品推广驱动因素和未满足的需求。这些访谈旨在引出可操作的决策标准以及影响采购和产品推广选择的实际限制因素。

将技术、供应链韧性和用户访问等方面的策略挑战整合起来，得出简洁的结论，有助于永续的决策。

总而言之，新冠病毒概念验证（PoC）检测领域已发展成为一个复杂的生态系统，其中技术、供应链、法规和使用者体验相互作用，共同决定商业性和公共卫生结果。重点正从紧急部署转向永续且具韧性的模式，以支援分散式检查、强有力的监测以及与医疗服务体系的整合。透过产品类型、应用、侦测技术、检体类型、最终用户和分销管道等细分观点，可以发现具体的创新和策略投资机会。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：新冠病毒检测即时检验试剂盒市场：依产品类型划分

  • 消耗品
  • 装置
  • 成套工具

第九章：依检测技术分類的新冠病毒即时检测试剂盒市场

  • 抗体
  • 抗原
  • LAMP

第十章：检体类型分類的 COVID-19 检测即时检验试剂盒市场

  • 鼻咽拭子
  • 口腔和咽拭子
  • 唾液

第十一章：新冠病毒检测即时检验试剂盒市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：新冠病毒检测即时检验试剂盒市场：依应用领域划分

  • 临床检测
  • 研究
  • 自我检查
  • 监视

第十三章：新冠病毒检测即时检验试剂盒市场：依最终用户划分

  • 诊断中心
  • 居家照护
  • 医院

第十四章：新冠病毒即时检测试剂盒市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：新冠病毒检测即时检验试剂盒市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：新冠病毒检测即时检验试剂盒市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国新冠病毒检测即时检验试剂盒市场

第十八章：中国新冠病毒检测即时检验试剂盒市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Aurora Biomed Inc.
  • Becton Dickinson and company
  • BGI Group
  • BioFire Diagnostics
  • bioMerieux SA
  • Cerba HealthCare SAS by EQT
  • Co-Diagnostics, Inc.
  • Convergent Technologies GmbH & Co. KG
  • Cue health Inc.
  • DiaSorin SpA
  • Drummond Scientific Company
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Quest Diagnostics
  • Quidel Corporation
  • SD Biosensor Inc.
  • Seegene, Inc
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-205091A88F53

The COVID-19 Detection PoC Kits Market was valued at USD 3.86 billion in 2025 and is projected to grow to USD 4.14 billion in 2026, with a CAGR of 7.18%, reaching USD 6.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.86 billion
Estimated Year [2026] USD 4.14 billion
Forecast Year [2032] USD 6.28 billion
CAGR (%) 7.18%

An authoritative introduction framing how rapid pandemic-era innovation has matured into complex sustainable diagnostic ecosystems across clinical and decentralized settings

The COVID-19 detection proof-of-concept (PoC) kits landscape has evolved from an emergent emergency response into a nuanced and sustained component of diagnostic resilience. In the early phases of the pandemic, rapid assay development and emergency use authorizations prioritized speed over scale, but the intervening years have emphasized robustness, supply continuity, and integration with clinical workflows. This evolution has left the industry with a layered ecosystem of consumables, instruments, and kits designed for diverse settings from centralized laboratories to decentralized point-of-care sites.

As public health priorities shift toward endemic management, stakeholders across clinical testing, research, self-testing, and surveillance applications are demanding solutions that balance sensitivity, usability, and cost efficiency. Detection technologies such as antibody, antigen, and loop-mediated isothermal amplification (LAMP) assays are now assessed not only on analytic performance but on manufacturability, distribution logistics, and regulatory stability. Concurrently, sample collection methods including nasopharyngeal swabs, oropharyngeal swabs, and saliva have prompted iterative improvements in kit design and user instructions to reduce variability and enable wider adoption across diagnostic centers, home care environments, and hospital settings.

The introduction sets the stage for deeper analysis by framing these dynamics within the operational realities of manufacturers, distributors, clinical adopters, and public health authorities. It highlights the central trade-offs organizations face: the need to move beyond emergency deployment models toward sustainable, scalable business and supply chain practices while preserving rapid responsiveness to epidemiological shifts. This balance underpins the subsequent sections, which detail transformative shifts, policy impacts, segmentation nuances, regional patterns, competitive behavior, actionable recommendations, and the methodological approach underpinning the insights presented.

A strategic analysis of the major structural shifts reshaping diagnostic workflows, supply resilience, and technology convergence that redefine proof-of-concept testing

The detection PoC kit environment has been reshaped by several transformative shifts that together redefine how stakeholders approach testing strategy and product development. First, decentralization of diagnostic workflows has become a central imperative. Health systems and private providers increasingly prefer PoC solutions that deliver reliable results outside traditional laboratories, which encourages manufacturers to prioritize user-centric design, simplified sample collection, and integration with digital reporting platforms. Over time, regulatory agencies have adapted pathways for such decentralized tools, which in turn speeds adoption but also raises expectations for post-market surveillance and real-world performance evidence.

Second, supply chain resilience has emerged as a strategic cornerstone. The pandemic exposed single-source dependencies for critical components such as reagents, swabs, and electronic assay modules, prompting investment in diversified sourcing, regional manufacturing capacity, and inventory strategies that buffer against disruption. Third, technology convergence is accelerating: lateral flow immunoassays, antigen detection formats, antibody serology, and LAMP-based nucleic acid amplification are being engineered with complementary strengths to address different clinical and surveillance needs. This technological pluralism enables more tailored diagnostic pathways, but it also complicates procurement and requires new frameworks for comparative evaluation.

Fourth, data integration and interoperability have come to the fore. The utility of PoC testing is amplified when results feed effortlessly into electronic health records, public health dashboards, and patient-facing applications. As a result, software and digital infrastructure partnerships are now integral to product value propositions. Lastly, commercial models have diversified beyond direct sales to include subscription services for reagent replenishment, platform-as-a-service offerings for instrument access, and bundled solutions that combine test kits with telehealth and care navigation. Together, these shifts transform PoC kits from isolated consumables into nodes within broader clinical, logistical, and digital ecosystems.

A rigorous assessment of how tariff-driven trade dynamics are reshaping procurement, manufacturing localization, and cost structures across the diagnostic supply chain

The introduction of heightened tariff measures has a cascading impact across the COVID-19 detection PoC kit value chain, affecting raw materials, finished products, and cross-border distribution strategies. Tariffs alter landed costs for consumables and instruments, prompting manufacturers and procurement teams to reassess sourcing strategies and inventory planning. For manufacturers that rely on specialized components produced abroad, tariffs can incentivize nearshoring and the development of alternate supplier relationships, which in turn can improve long-term resilience but may require near-term capital investment and process qualification.

From a commercial perspective, increased import costs compress margins for suppliers unless offset by price adjustments further downstream. Buyers such as hospitals and diagnostic centers face a tension between cost containment and the need to secure reliable supply, leading some organizations to consolidate suppliers or negotiate longer-term contracts to stabilize unit costs and delivery schedules. Distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies may reconfigure stocking policies and order cycles to mitigate cost volatility and preserve service continuity.

Policy responses to tariff regimes also shape market behavior. Governments may pair tariffs with incentives for domestic manufacturing, offering grants or tax benefits that accelerate regional production capacity. These incentives can create a bifurcated landscape where high-volume standardized products are localized while niche, specialized reagents continue to be imported. The cumulative effect is an industry in transition: operational decisions increasingly prioritize supply chain adaptability and regulatory compliance, and strategic planning must incorporate scenarios that account for tariff-driven cost differentials and their implications for procurement, pricing, and market access.

An integrated segmentation-driven perspective revealing where product design, regulatory evidence, and distribution strategies intersect to maximize adoption and clinical utility

Segmentation analysis provides a framework to understand where innovation, adoption, and commercial opportunity intersect within the PoC kit landscape. When viewed through the lens of product type-consumables, instruments, and kits-distinct operational and commercial considerations emerge. Consumables demand high-volume, repeatable supply and tight quality controls, instruments require capital expenditure justification and lifecycle support, and kits combine reagents and instructions in formats optimized for specific use environments. Each category follows different purchasing cycles and support needs, which in turn affects go-to-market strategies for suppliers.

Application-based segmentation-clinical testing, research, self-testing, and surveillance-highlights differences in performance requirements and user experience. Clinical testing prioritizes validated sensitivity and integration with clinical workflows, research emphasizes flexibility and assay customization, self-testing demands simplicity and robust user instructions to maintain accuracy outside professional settings, and surveillance systems focus on throughput and cost efficiency for population-level monitoring. These application distinctions influence how detection technologies are positioned and validated.

Detection technology segmentation across antibody, antigen, and LAMP modalities reveals divergent use cases and validation pathways. Antibody tests are informative for seroprevalence and past exposure, antigen assays are optimized for rapid detection of active infection with a balance of speed and sensitivity, and LAMP-based approaches offer portable nucleic acid amplification without the complexity of traditional PCR, making them attractive for decentralized settings. Sample type segmentation-nasopharyngeal swab, oropharyngeal swab, and saliva-affects user experience, biosafety considerations, and analytic sensitivity, and choices among these types influence kit design and instructions for use.

End user segmentation into diagnostic centers, home care, and hospitals underscores varying procurement models and technical support expectations. Diagnostic centers often demand batch testing throughput and validated assay comparability, home care prioritizes ease of use and clear interpretability, while hospitals require solutions that integrate into inpatient care pathways with high reliability. Distribution channel segmentation encompassing hospital pharmacy, online pharmacy, and retail pharmacy speaks to accessibility and patient behavior; online channels expand reach and convenience but raise questions about proper storage and guidance, whereas hospital pharmacies anchor medically supervised distribution. Synthesizing these segmentation lenses unveils where product development should target improvements in usability, regulatory evidence, supply planning, and digital integration to meet the specific needs of each stakeholder group.

A nuanced regional synthesis explaining how regulatory frameworks, manufacturing capacity, and healthcare delivery models drive differential adoption of PoC diagnostic solutions

Regional dynamics exert a profound influence on how PoC diagnostic products are developed, regulated, and deployed. In the Americas, heterogeneous regulatory frameworks coexist with sophisticated private healthcare networks and significant purchasing power, which accelerates adoption of advanced point-of-care instruments while also creating pockets of demand for affordable self-testing and surveillance tools. The region's large domestic manufacturing base can be leveraged to mitigate supply chain disruptions, yet disparities in access across urban and rural settings persist and require differentiated distribution approaches.

In Europe, Middle East & Africa, regulatory harmonization efforts and collaborative public health initiatives drive demand for interoperable testing solutions that can be scaled across multiple health systems. The region features a mix of high-volume centralized laboratory capability and emerging decentralized testing programs, particularly where surveillance infrastructure is being strengthened. Local procurement policies and reimbursement models vary, influencing which technologies gain traction and how suppliers structure market entry and partnership strategies.

Asia-Pacific presents a diverse ecosystem ranging from high-capacity manufacturing hubs to rapidly expanding community testing programs. Strong manufacturing ecosystems in several countries support both domestic supply and export-oriented production, and regulatory authorities have shown flexibility in approving innovative diagnostic pathways. Adoption of self-testing formats and digital integration in healthcare delivery is accelerating in urban centers, while rural and remote areas necessitate robust, low-resource-compatible solutions. Across all regions, cross-border collaboration, public-private partnerships, and targeted investment in local production capacity will shape the availability and sustainability of PoC diagnostics, with regional priorities guiding the mix of technologies, sample modalities, and distribution channels deployed.

An evidence-based examination of how strategic partnerships, platform modularity, and total-solution offerings are redefining competitive advantage in diagnostic development

Competitive behavior among firms in the PoC detection space is characterized by rapid product iteration, strategic partnerships, and flexible commercial models. Manufacturers are increasingly pursuing modular platform strategies that allow for quick reconfiguration of assays and reagents to respond to shifts in pathogen biology or market demand. Strategic partnerships with reagent suppliers, contract manufacturers, and software integrators have become central to accelerating time-to-market and scaling distribution capabilities.

Collaboration between diagnostic developers and healthcare providers is another prevalent trend, where early clinical validation and feedback loops inform iterative design improvements. Licensing arrangements and joint ventures enable companies to extend geographic reach without assuming full manufacturing risk, and supply agreements with major institutional buyers help stabilize demand. At the same time, smaller innovators focus on niche applications or unique detection chemistries to differentiate their offerings, often positioning for acquisition or co-development with larger players.

Commercial differentiation increasingly relies on the total solution: assay performance coupled with instrument serviceability, reagent logistics, user training, and digital result management. Firms that invest in post-market support, clear training materials for non-laboratory users, and evidence generation in real-world settings strengthen long-term adoption. Overall, the competitive landscape rewards agility, depth of partnerships, and the ability to provide validated, user-friendly solutions across varied care environments.

Practical strategic recommendations for leaders to build resilient supply chains, enhance user-focused design, and align commercial models with evolving healthcare demands

Industry leaders should pursue a multi-pronged approach that prioritizes supply resilience, user-centered design, and strategic commercialization to capitalize on evolving demand for PoC diagnostics. First, diversify supply chains to reduce single-source dependencies by qualifying alternate suppliers, enabling dual sourcing for critical reagents and components, and investing in regional manufacturing capabilities. This reduces exposure to trade disruptions and tariff volatility while supporting faster response to localized surges in demand.

Second, focus on product usability across varied end users by simplifying sample collection, enhancing instructions for non-professional administration, and embedding fail-safes that reduce user error. Prioritizing formats that accommodate nasopharyngeal, oropharyngeal, and saliva specimens can broaden use cases and improve user acceptance. Third, strengthen digital integration to ensure seamless reporting into clinical records and public health systems, which enhances the value proposition for institutional buyers and supports surveillance objectives.

Fourth, adopt flexible commercial models including reagent replenishment subscriptions and instrument-as-a-service to lower barriers to adoption for smaller facilities. Fifth, engage proactively with regulators and payers to establish evidence generation plans that demonstrate real-world effectiveness in distinct applications such as clinical testing, research, self-testing, and surveillance. Finally, cultivate partnerships across distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies to align stocking practices, training, and supply visibility. These coordinated actions will position organizations to deliver resilient, scalable solutions that meet both clinical and public health needs.

A transparent methodology that blends primary stakeholder interviews and rigorous secondary verification to produce actionable, ethically sourced insights without numeric market estimations

The research methodology underpinning these insights combined structured primary research with systematic secondary analysis to ensure robust and verifiable findings. Primary inputs included semi-structured interviews with stakeholders across the value chain-product developers, procurement officers, clinical users, distribution partners, and regulatory advisors-to capture operational realities, adoption drivers, and unmet needs. These interviews were designed to elicit practical decision criteria and real-world constraints that influence procurement and deployment choices.

Secondary analysis synthesized regulatory guidance, peer-reviewed literature, technical white papers, and publicly available policy documents to contextualize technological performance characteristics and regional regulatory environments. Data triangulation was applied to validate qualitative insights against multiple sources, reducing bias and enhancing reliability. Where appropriate, scenario analysis was employed to evaluate how changes such as tariff adjustments or supply interruptions could affect strategic decisions, focusing on operational levers rather than numerical forecasts.

Limitations include rapidly evolving epidemiological contexts and emerging technological innovations that may shift priorities; therefore, findings emphasize durable strategic considerations and process-oriented recommendations. Ethical considerations were observed in primary research by anonymizing proprietary information and securing consent for participation. The methodology reflects a pragmatic balance between depth of qualitative insight and breadth of secondary evidence to produce actionable guidance for stakeholders across the PoC diagnostic ecosystem.

A succinct conclusion synthesizing strategic imperatives across technology, supply resilience, and user-access considerations to inform sustainable decision-making

In summary, the COVID-19 PoC detection landscape has matured into a complex ecosystem where technology, supply chains, regulation, and user experience interact to determine commercial and public health outcomes. The emphasis has shifted from emergency deployment to sustainable, resilient models that support decentralized testing, robust surveillance, and integration with healthcare delivery systems. Segmentation lenses across product type, application, detection technology, sample type, end user, and distribution channel reveal targeted opportunities for innovation and strategic investment.

Regional dynamics and policy instruments, including trade measures and incentives for local production, will continue to influence where and how solutions are manufactured and distributed. Competitive advantage will accrue to organizations that combine modular product platforms, strategic partnerships, and comprehensive service offerings with clear evidence of real-world performance. Ultimately, the most successful strategies will align technical excellence with pragmatic considerations of supply resilience, user accessibility, and regulatory engagement to ensure diagnostic tools reliably serve both clinical care and public health objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COVID-19 Detection PoC Kits Market, by Product Type

  • 8.1. Consumables
  • 8.2. Instruments
  • 8.3. Kits

9. COVID-19 Detection PoC Kits Market, by Detection Technology

  • 9.1. Antibody
  • 9.2. Antigen
  • 9.3. Lamp

10. COVID-19 Detection PoC Kits Market, by Sample Type

  • 10.1. Nasopharyngeal Swab
  • 10.2. Oropharyngeal Swab
  • 10.3. Saliva

11. COVID-19 Detection PoC Kits Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. COVID-19 Detection PoC Kits Market, by Application

  • 12.1. Clinical Testing
  • 12.2. Research
  • 12.3. Self Testing
  • 12.4. Surveillance

13. COVID-19 Detection PoC Kits Market, by End User

  • 13.1. Diagnostic Centers
  • 13.2. Home Care
  • 13.3. Hospitals

14. COVID-19 Detection PoC Kits Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. COVID-19 Detection PoC Kits Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. COVID-19 Detection PoC Kits Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States COVID-19 Detection PoC Kits Market

18. China COVID-19 Detection PoC Kits Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Aurora Biomed Inc.
  • 19.7. Becton Dickinson and company
  • 19.8. BGI Group
  • 19.9. BioFire Diagnostics
  • 19.10. bioMerieux SA
  • 19.11. Cerba HealthCare S.A.S. by EQT
  • 19.12. Co-Diagnostics, Inc.
  • 19.13. Convergent Technologies GmbH & Co. KG
  • 19.14. Cue health Inc.
  • 19.15. DiaSorin S.p.A.
  • 19.16. Drummond Scientific Company
  • 19.17. F. Hoffmann-La Roche AG
  • 19.18. Hologic, Inc.
  • 19.19. Mylab Discovery Solutions Pvt. Ltd.
  • 19.20. Quest Diagnostics
  • 19.21. Quidel Corporation
  • 19.22. SD Biosensor Inc.
  • 19.23. Seegene, Inc
  • 19.24. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COVID-19 DETECTION POC KITS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COVID-19 DETECTION POC KITS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ANTIGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ANTIGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ANTIGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY LAMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY LAMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY LAMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY OROPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY OROPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY OROPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY CLINICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY CLINICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY CLINICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SELF TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SELF TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SELF TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. G7 COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NATO COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL COVID-19 DETECTION POC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, BY DETECTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA COVID-19 DETECTION POC KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)